CSL's Financial Results
Please click the link below to view our most recent and historic Full Year and Half Year Financial Results information.
More InformationSearch Results
429 results found-
The Group adopted AASB 16 Leases ("AASB 16") from 1 We selected a sample of lease agreements to determine the July 2019, which resulted in the recognition of $926 appropriateness of the udgements and accounting million of right-of-use assets and $1,004 million lease treatments applied in determining the transition ad ustment liabilities at adoption date.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
NPAT at 30 June 2019 resulted in an above target performance, however CFO was below target (and above threshold).
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf -
incurred by Australia in 2019 has resulted in the Over A$600m has been invested in manufacturing Australian business making a loss in 2019.
https://www.csl.com/-/media/csl/tax-transparency-reports/csl-limited-tax-transparency-report-2019.pdf -
on Aboriginal health research and opportunities in 2019, resulting in a collaboration and grant application with Employment and CSL's Translational Research team.
https://www.csl.com/-/media/shared/documents/reconciliation-action-plan/csl-reflect-reconciliation-action-plan-rap-2023.pdf -
CSL conducts clinical trials in accordance with our Code of Conduct and the current Guideline for Good Clinical Practice (GCP) of the International Conference on Harmonization (ICH).
https://www.csl.com/research-and-development/clinical-studies/research-practices -
This report is based on 2019 data from Seqirus Vaccines Ltd. UNDERSTANDING GENDER PAY GAP
https://www.csl.com/-/media/shared/documents/seqirus-disclosures/disclosures-2019/seqirus-gender-pay-gap_2019_final.pdf -
Vita means life. It's also where CSL shares news and inspiring stories, posted every business day.
https://www.csl.com/we-are-csl/vita-original-stories/2019 -
This latest announcement follows a previous pandemic vaccine reservation agreement with CSL Seqirus, initiated in 2019, and a contract awarded in June last year to supply 665,000 doses of pre-pandemic (zoonotic) influenza vaccine for fifteen EU and EEA Member States.
https://newsroom.csl.com/2025-04-29-CSL-Seqirus,-a-Global-Leader-in-Pandemic-Preparedness-and-Outbreak-Response,-Signs-an-Agreement-with-the-European-Commission-to-Support-Pandemic-Preparedness-Plans